Get started
Author

Guilherme Rossato de Almeida

Observed names: G R Almeida, G. Rossato de Almeida, Guilherme Rosato de Almeida, Guilherme Rossato, Guilherme Rossato De Almeida
ORCID: 0009-0000-6073-6130
Observed ORCID: 0009-0000-6073-6130
OpenAlex ID: A5102681663
Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
2024 · Maria Inez Dacoregio, Isabella Michelon, et al. · The Breast · 25
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
2025 · Federica Pecci, Rohit Thummalapalli, et al. · Clinical Cancer Research · 12
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al. · Clinical Cancer Research · 10
PDF
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies
2026 · M. Aldea, S.M. Lenahan, et al. · Annals of Oncology · 9
Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report
2025 · Eleonora Gariazzo, Sanna Laaksonen, et al. · JCO Precision Oncology · 3
Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study
2025 · G R Almeida, G K Zanetta, et al. · Endocrine Oncology · 1
A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma
2026 · Henrique Jin Son Kim, Murilo Lauria Freire Ribeiro, et al. · Journal of Gastrointestinal Cancer
PDF
Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report
2026 · Federica Pecci, Xinan Wang, et al. · Journal of Thoracic Oncology
OA01.04: Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
2026 · Federica Pecci, Xinan Wang, et al. · Journal of Thoracic Oncology
267P Can patients (pts) with neuroendocrine tumors (NET) and asymptomatic elevation of 24h urinary 5-hydroxyindoleacetic acid (u5-HIAA) develop carcinoid syndrome (CS) complications?
2026 · H.J.S. Kim, L.M.D.S. Oliveira, et al. · Annals of Oncology
PDF
A meta-analysis on outcomes of zanidatamab plus chemotherapy in patients with advanced HER2-gastroesophageal adenocarcinoma.
2026 · Henrique Jin Son Kim, Leonardo Gil Santana, et al. · Journal of Clinical Oncology
PDF
Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer
2026 · Larissa Garcia, Guilherme Rossato, et al. · Journal of Gastrointestinal Oncology
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer
2026 · Luciana de Moura Leite, Guilherme Rossato de Almeida, et al. · Breast Cancer Research and Treatment
PDF
Total neoadjuvant treatment in locally advanced rectal cancer: A retrospective multicentre cohort analysis in three cancer centres in Brazil.
2026 · Rafael Vanin De Moraes, Elson Santos Neto, et al. · Journal of Clinical Oncology
PDF
1000P Thromboembolic risk in ALK, ROS1 or RET-rearranged advanced non-small cell lung cancer (aNSCLC): A multicenter competing-risk analysis
2025 · M. Aldea, H. Heiling, et al. · Annals of Oncology
Data from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
Supplementary Figure 6 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 9 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 7 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 5 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Tables from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 8 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 1 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 3 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Supplementary Figure 2 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
2025 · Federica Pecci, Hui Li, et al.
PDF
Works count: 42
Citation count: 60
H-index: 4
I10-index: 3
Year
Topic
Type